Cabozantinib (XL184, BMS-907351)

Catalog No.S1119

Cabozantinib (XL184, BMS-907351) Chemical Structure

Molecular Weight(MW): 501.51

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 470 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.

    Cancer Discov 2014 4(7), 816-27. Cabozantinib (XL184, BMS-907351) purchased from Selleck.

    Imaging and quantification of cabozantinib (XL-184) effects on EMT in vitro. A-C, Western blot analysis of E-cadherin and c-Met expression in the XL-184-treated RFPþ tumor cells. D-F, GFP imaging merged with bright field view of the XL-184–treated RFPþ tumor cells.

    Cancer Res, 2016, 76(8):2094-104. Cabozantinib (XL184, BMS-907351) purchased from Selleck.

  • Cabozantinib specifically inhibited the phosphorylation of FLT3 (A) and downstream signaling molecules such as STAT5, Akt and ERK1/2 in FLT3-ITD MV4-11 cells (B). By contrast, the phosphorylation of downstream FLT3 signaling molecules was unaffected by cabozantinib in FLT3 wild-type OCI-AML3 cells (C). Cells were treated with cabozantinib for 2 h, and the expression of pFLT3, FLT3, pSTAT5, STAT5, pAkt, Akt, pErk1/2, and Erk1/2 was measured by Western blotting.

    Cancer Lett, 2016, 376(2):218-25. Cabozantinib (XL184, BMS-907351) purchased from Selleck.

    Cabozantinib reduces viability and spheroid and colony formation of GCTB stromal cells. (a) Adherent-growing GCTB stromal cells derived from three different patients were left untreated (CO) or were treated with cabozantinib (10 uM, XL184) or methotrexate (100 uM, MTX). Seventy-two hours later, the viability was measured by the MTT assay, and the control was set to 100%. (b) Spheroidal cultures were established as described in b. After spheroid formation, the cells were left untreated or were treated as described above. Seven days later, spheroids were photographed, and the number and volume of spheroids (spheroid surface) were determined. The data shown are the MD. (*P<0.05; **P<0.01).

    Cell Death Dis 2014 5, e1471. Cabozantinib (XL184, BMS-907351) purchased from Selleck.

  • The effect of cabozantinib on the accumulation of Dox and Rho123. (A) Fluorescence microscopy observation of the accumulation of Dox and Rho123. The scale bars represent 100 uM. (B) The accumulation of Dox and Rho123 was measured by flow cytometric analysis. The data were analysed using Kaluza software and are presented as fold-change in fluorescence intensity relative to the control HepG2/adr cells. The results are shown as the mean ± SD of three independent trials. *P < 0.05 vs. the control group.

    Liver Int 2014 10.1111/liv.12524. Cabozantinib (XL184, BMS-907351) purchased from Selleck.

    Inhibition of breast cancer cell growth using XL184. MCF-7 breast cancer cells were treated with increasing concentrations of XL-184 for 5 days. Cell number was measured  using a colorimetric growth assay (crystal violet stain) and expressed relative to DMSO treated control cells.

     

    Christina W Yde/CDM Danish Cancer Society Research Center Denmark. Cabozantinib (XL184, BMS-907351) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.
Targets
VEGFR2/KDR [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
0.035 nM 1.3 nM
In vitro

XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E98NT  NIHqV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMlAyNTFyIN88US=> MVzEUXNQ NFHmb2FKSzVyPUi5JI5O NUfXTXNuOjN2OESwNFY>
SNU-5  NH7TSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHZ[XJKSzVyPTCxPUBvVQ>? M1fSNFIyQTJ4MUmx
Hs746T  NITnUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlwOTDuUS=> NWSyfY5kOjF7Mk[xPVE>
SNU-1  M4TDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:2U2lEPTB;NUKyN{BvVQ>? MmTsNlE6OjZzOUG=
SNU-16 NF;OcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTlfohKSzVyPUGxOFkhdk1? M2Pid|IyQTJ4MUmx
MDA-MB-231 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;tTWM2OD1iNkSyNUBvVQ>? MX:yNVkzPjF7MR?=
U87MG NWOwfXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF6NUGgcm0> MlnENlE6OjZzOUG=
H441  NXfBZZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTtW3h3UUN3ME2yNVcxOCCwTR?= MUOyNVkzPjF7MR?=
H69 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnIeI1JUUN3ME2yNFIxOCCwTR?= NHPlZ3UzOTl{NkG5NS=>
PC3 M1X0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3kOZNKSzVyPUGwPFAxKG6P M2jnclIyQTJ4MUmx
MTC-TT NX3uZnN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorDTWM2OD1yLkC0JEshOC5yMzFOwG0> M{XCU|IyPDdyOUm1
MZ-CRC MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PSVGlEPTB-IEWg{txO MXOyNVQ4ODl7NR?=
TPC-1 NVLjW4VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHsTWM2OD1yLkC2JEshOC5yMjFOwG0> MXSyNVQ4ODl7NR?=

... Click to View More Cell Line Experimental Data

In vivo XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

Protocol

Cell Research:

[2]

+ Expand
  • Cell lines: ST88-14, STS26T, and MPNST724
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 48 hours
  • Method:

    Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
  • Formulation: Suspended at a concentration of 5 mg/mL in sterile saline or water
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 501.51
Formula

C28H24FN3O5

CAS No. 849217-68-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03586973 Recruiting Advanced Hepatocellular Carcinoma Takeda July 9 2018 Phase 2
NCT02496208 Recruiting Bladder Small Cell Neuroendocrine Carcinoma|Clear Cell Renal Cell Carcinoma|Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma Plasmacytoid Variant|Kidney Medullary Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Penile Carcinoma|Metastatic Renal Cell Carcinoma|Renal Pelvis Urothelial Carcinoma|Sarcomatoid Renal Cell Carcinoma|Squamous Cell Carcinoma of the Penis|Stage III Bladder Adenocarcinoma AJCC v6 and v7|Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Penile Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Renal Pelvis Cancer AJCC v7|Stage III Ureter Cancer AJCC v7|Stage III Urethral Cancer AJCC v7|Stage IIIa Penile Cancer AJCC v7|Stage IIIb Penile Cancer AJCC v7|Stage IV Bladder Adenocarcinoma AJCC v7|Stage IV Bladder Squamous Cell Carcinoma AJCC v7|Stage IV Bladder Urothelial Carcinoma AJCC v7|Stage IV Penile Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Renal Pelvis Cancer AJCC v7|Stage IV Ureter Cancer AJCC v7|Stage IV Urethral Cancer AJCC v7|Ureter Urothelial Carcinoma|Urethral Urothelial Carcinoma National Cancer Institute (NCI) July 9 2015 Phase 1
NCT02867592 Recruiting Adrenal Cortex Carcinoma|Alveolar Soft Part Sarcoma|Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Parts|Clear Cell Sarcoma of Soft Tissue|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|MITF Positive|Osteosarcoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Central Nervous System Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Soft Tissue Sarcoma Excluding Rhabdomyosarcoma|Recurrent Thyroid Gland Medullary Carcinoma|Refractory Ewing Sarcoma|Refractory Malignant Central Nervous System Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Soft Tissue Sarcoma Excluding Rhabdomyosarcoma|Renal Cell Carcinoma|Rhabdomyosarcoma|Soft Tissue Sarcoma Excluding Rhabdomyosarcoma|Solid Neoplasm|Thyroid Gland Medullary Carcinoma|Wilms Tumor National Cancer Institute (NCI) May 8 2017 Phase 2
NCT01630590 Active not recruiting Prostate Cancer M.D. Anderson Cancer Center|Exelixis|High Impact Clinical Research Support Program January 8 2014 Phase 2
NCT01835158 Active not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 National Cancer Institute (NCI) July 8 2013 Phase 2
NCT01811212 Completed Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma National Cancer Institute (NCI)|Exelixis May 8 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) supplier | purchase Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) cost | Cabozantinib (XL184, BMS-907351) manufacturer | order Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID